The Prostate Cancer Foundation is collaborating with the University of California, San Franciscio (UCSF) and the San Francisco VA Health Care System (SFVAHCS) to launch the Drew Foundation Precision Oncology Center of Excellence.
The Center of Excellence will deliver best-in-class precision oncology treatments to Veterans with prostate cancer.
In a press release by PCF, Jonathan W. Simons, MD, PCF president and CEO, said: “PCF is committed to continuing to expand our partnership with the VA to advance cutting-edge research and care for Veterans with prostate cancer. Partnering with the University of California, San Francisco brings top expertise to our precision oncology efforts serving our nation’s Veterans.
“UCSF researchers co-developed the latest FDA-approved PSMA-PET scan which zeroes in on prostate cancer that has spread through the body so it can be better targeted for treatment. It is our duty to ensure that no Veteran is left behind when such medical breakthroughs come to the clinic.”
Each year more than 15,000 men in the Veterans Affairs health system are diagnosed with prostate cancer. This makes it the most commonly diagnosed cancer among Veterans.
It’s believed that Precision Medicine is the key to ending deaths from prostate cancer.
Alan Ashworth, PhD, FRS, president of the UCSF Helen Diller Family Comprehensive Cancer Center said: ”The PCF’s commitment to ensuring veterans have access to cutting-edge cancer therapies is critical, and UCSF appreciates our longstanding relationship with the PCF and the advances it enables.
“The team of UCSF physician scientists involved with the new Drew Foundation Precision Oncology Center of Excellence at the SFVAHCS are leaders in the field and will contribute even more to our use of precision medicine to treat prostate cancer.”
Read more about the collaboration here.